Elevated expression levels of the co-activator CITED2 (CBP/p300-interacting-transactivator-with-an-ED-rich-tail 2) has been associated with maintenance of both normal and leukemic hematopoietic stem and progenitor cells (HSPCs).460 Moreover, a subset of AML patients displayed higher expression levels of CITED2 in CD34(+) cells as compared with normal CD34(+) HSPCs.461 CITED2 also regulates p53 activity to promote AML, and therefore it can be a potential target for AML therapy. Here, TP53 is linked to acute myeloid leukemia.